drugset / Trial / NCT04090710
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Phase 2
Active not recruiting
66 enrolled
Ontario Clinical Oncology Group (OCOG)
Bristol-Myers Squibb · collabHamilton Health Sciences Corporation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
Timeline
- Start
- 2020-01-29
- Primary completion
- 2026-06-30
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Comparator | Nivolumab | Monoclonal antibody | 240 mg | — |
| Comparator | Nivolumab | Monoclonal antibody | 480 mg | — |